Fdf03 antibodies and uses thereof

Abstract

The present invention relates to methods for identifying and using modulators of FDF03 biological activity in vitro and in vivo that are useful in the treatment of cancer.

What is claimed is: 
     
         1 . A method for inhibiting tumor growth in a subject, comprising administering to a subject in need thereof an agent that stimulates or enhances FDF03 inhibitory receptor biological activity. 
     
     
         2 . The method of  claim 1 , wherein the agent is an agonist or partial-agonist antibody or antibody fragment thereof specific for the FDF03 inhibitory receptor. 
     
     
         3 . The method of  claim 2 , wherein the antibody is a humanized, fully human or chimeric antibody. 
     
     
         4 . The method of  claim 1 , wherein the tumor is a primary or a metastatic tumor. 
     
     
         5 . The method of  claim 1 , wherein the subject is a human. 
     
     
         6 . A method for reducing metastatic burden in a subject comprising administering to a subject in need thereof an agent that stimulates or enhances FDF03 inhibitory receptor biological activity. 
     
     
         7 . The method of  claim 6 , wherein the agent is an agonist or partial-agonist antibody, or antibody fragment thereof specific for the FDF03 inhibitory receptor. 
     
     
         8 . The method of  claim 7 , wherein the antibody is a humanized, fully human or chimeric antibody. 
     
     
         9 . The method of  claim 6 , wherein the subject is a human. 
     
     
         10 . A method for inhibiting tumor growth in a subject, comprising administering to a subject in need thereof an agent that binds to an FDF03 inhibiting receptor and an FDF03 activating receptor. 
     
     
         11 . The method of  claim 10 , wherein the agent is a bispecific antibody or antibody fragment thereof that binds to the FDF03 inhibitory receptor and the FDF03 activating receptor. 
     
     
         12 . The method of  claim 11 , wherein the antibody is a humanized, fully human or chimeric antibody. 
     
     
         13 . The method of  claim 10 , wherein the tumor is a primary or a metastatic tumor. 
     
     
         14 . The method of  claim 10 , wherein the subject is a human 
     
     
         15 . A method for reducing metastatic burden, comprising administering to a subject in need thereof an agent that binds to an FDF03 inhibiting receptor and an FDF03 activating receptor. 
     
     
         16 . The method of  claim 15 , wherein the agent is a bispecific antibody or antibody fragment thereof that binds to the FDF03 inhibiting receptor and the FDF03 activating receptor. 
     
     
         17 . The method of  claim 16 , wherein the antibody is a humanized, fully human or chimeric antibody. 
     
     
         18 . The method of  claim 15 , wherein the subject is a human.